James K. McCloskey, MD, a specialist in leukemia, discusses how the treatment landscape has changed in recent years.

Following ASH 2023, a hematologist-oncologist discusses recent updates on approved and emerging therapies for patients with leukemia, highlighting the TRANSFORM-1 trial looking at navitoclax plus ruxolitinib.

Focusing on chronic myeloid leukemia, James K. McCloskey, MD, reviews the long-term results of the OPTIC trial presented at ASH 2023.

An expert on leukemia provides comprehensive insights on the subgroup analysis of the phase 3 PhALLCON study of ponatinib in Ph+ acute lymphoblastic leukemia.

James K. McCloskey, MD, provides an overview of key takeaways from recent studies presented at the 2023 ASH Annual Meeting in leukemia.

Dr McCloskey highlights challenges in adverse event management and discusses unmet needs in the treatment of patients with leukemia.

Lori A. Leslie, MD, a specialist in lymphoma, provides an overview of recent changes in the overall treatment landscape.

A hematologist-oncologist discusses a recent abstract looking at subcutaneous mosunetuzumab in the first line for patients with follicular lymphoma.

Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5.

Focusing on mantle cell lymphoma, Lori A. Leslie, MD, reviews the primary analysis of the SYMPATICO trial investigating ibrutinib-venetoclax combination therapy.

Clinical insights on managing adverse events associated with CAR T-cell therapy and measuring patient response, highlighting a phase 2 trial on prophylactic anakinra.

Looking to the future, Lori A. Leslie, MD, offers closing thoughts on unmet needs and potential improvements in the lymphoma treatment space.